MREO Investor Notice: Levi & Korsinsky Investigates Mereo BioPharma Group plc for Securities Law Violations

Core Viewpoint - Mereo BioPharma Group plc is under investigation for potential violations of federal securities laws following disappointing clinical trial results that led to a significant drop in stock price [1][2]. Group 1: Company Overview - Mereo BioPharma Group plc announced results from its Phase 3 ORBIT and COSMIC studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI) on December 29, 2025 [2]. - The studies did not achieve their primary efficacy endpoint of reducing the annualized clinical fracture rate compared to placebo [2]. Group 2: Stock Performance - Following the announcement of the clinical trial results, Mereo's stock price plummeted over 89%, opening at $0.25 per share [2]. Group 3: Legal Investigation - Levi & Korsinsky has commenced an investigation into Mereo BioPharma Group plc concerning potential violations of federal securities laws, inviting affected investors to explore recovery options [1][3].